A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)
100 项与 Intrexon T1D Partners LLC 相关的临床结果
0 项与 Intrexon T1D Partners LLC 相关的专利(医药)
100 项与 Intrexon T1D Partners LLC 相关的药物交易
100 项与 Intrexon T1D Partners LLC 相关的转化医学